Ceftobiprole: A novel, broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus

American Journal of Health-System Pharmacy

Volumn 67, Issue 12, 2010, Pages 983-993

  Dauner, Daniel G ^a,b   Nelson, Robert E ^c,d   Taketa, Donna C ^b  

^a UNIVERSITY OF MINNESOTA DULUTH   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c MeritCare Hospital   (United States)

^d NORTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

Binding; Ceftobiprole; Cephalosporins; Dosage schedule; Drug interactions; Excretion; Half life; Mechanism of action; Methicillin; Penicillins; Pharmacodynamics; Pharmacokinetics; Resistance; Spectrum microbial; Staphylococcal infections; Staphylococcus aureus; Toxicity

Indexed keywords

AMPICILLIN; AZTREONAM; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEFTOBIPROLE; CEFTRIAXONE; DAPTOMYCIN; IMIPENEM; LINEZOLID; METRONIDAZOLE; TEICOPLANIN; VANCOMYCIN;

ACINETOBACTER; ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; BETA HEMOLYTIC STREPTOCOCCUS; CITROBACTER; COAGULASE NEGATIVE STAPHYLOCOCCUS; COMMUNITY ACQUIRED PNEUMONIA; CONSTIPATION; DIARRHEA; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; ENDOCARDITIS; ENTEROBACTER; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; GASTROINTESTINAL SYMPTOM; HAEMOPHILUS INFLUENZAE; HEADACHE; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; HYPERSENSITIVITY REACTION; INJECTION SITE REACTION; INSOMNIA; KLEBSIELLA; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NAUSEA; NONHUMAN; PENICILLIN RESISTANT STREPTOCOCCUS PNEUMONIAE; PENICILLIN SUSCEPTIBLE STREPTOCOCCUS PNEUMONIAE; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; REVIEW; SERRATIA; SKIN INFECTION; STREPTOCOCCUS PNEUMONIAE; VOMITING;

EID: 79951910540     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp090285     Document Type: Review

References (52)

1. Klevens RM, Morrison MA, Nadle J et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA. 2007; 298:1763-71. (Pubitemid 47598444)
2. Moran GJ, Krishnadasan A, Gorwitz RJ et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006; 355:666-74.
3. Micek ST. Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis. 2007; 45(suppl 3):S184-90.
4. Maclayton DO, Hall RG 2nd. Pharmacologic treatment options for nosocomial pneumonia involving methicillinresistant Staphylococcus aureus. Ann Pharmacother. 2007; 41:235-44. (Pubitemid 46340054)
5. Paladino JA. Linezolid: an oxazolidinone antimicrobial agent. Am J Health-Syst Pharm. 2002; 59:2413-25. (Pubitemid 36014019)
6. Kasbekar N. Tigecycline: a new glycylcycline antimicrobial agent. Am J Health-Syst Pharm. 2006; 63:1235-43. (Pubitemid 44025089)
7. Entenza JM, Hohl P, Heinze-Krauss I et al. BAL9141, a novel extended-spectrum cephalosporin active against methicillin resistant Staphylococcus aureus in treatment of experimental endocarditis. Antimicrob Agents Chemother. 2002; 46:171-7. (Pubitemid 34031620)
8. Hebeisen P, Heinze-Krauss I, Angehrn P et al. In vitro and in vivo properties of RO 63-9141, a novel broad-spectrum cephalosporin with activity against methicillinresistant staphylococci. Antimicrob Agents Chemother. 2001; 45:825-36.
9. Jones RN, Deshpande LM, Mutnick AH. In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. J Antimicrob Chemother. 2002; 50:915-32.
10. Murthy B, Schmitt-Hoffmann A. Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity. Clin Pharmacokinet. 2008; 47:21-33. (Pubitemid 350260886)
11. Bush K, Heep M, Macielag MJ et al. Anti- MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy. Expert Opin Investig Drugs. 2007; 16:419-29. (Pubitemid 46554461)
12. Noel GJ. Clinical profile of ceftobiprole, a novel beta-lactam antibiotic. Clin Microbiol Infect. 2007; 13(suppl 2):25-9. (Pubitemid 46711386)
13. Davies TA, Page MG, Shang W et al. Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. Antimicrob Agents Chemother. 2007; 51:2621-4. (Pubitemid 47047351)
14. Kosowska K, Hoellman DB, Lin G et al. Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin. Antimicrob Agents Chemother. 2005; 49:1932-42. (Pubitemid 40631609)
15. Arias CA, Singh KV, Panesso D et al. Evaluation of ceftobiprole medocaril against Enterococcus faecalis in a mouse peritonitis model. J Antimicrob Chemother. 2007; 60:594-8. (Pubitemid 47299874)
16. Pillar CM, Aranza MK, Shah D et al. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin. J Antimicrob Chemother. 2008; 61:595-602.
17. Davies TA, Shang W, Bush K. Activities of ceftobiprole and other beta-lactams against Streptococcus pneumoniae clinical isolates from the United States with de- fined substitutions in penicillin-binding proteins PBP 1a, PBP 2b, and PBP 2x. Antimicrob Agents Chemother. 2006; 50:2530-2.
18. Fritsche TR, Sader HS, Jones RN. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY antimicrobial surveillance program (2005-2006). Diagn Microbiol Infect Dis. 2008; 61:86-95.
19. Goldstein EJ, Citron DM, Merriam CV et al. In vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infections. Antimicrob Agents Chemother. 2006; 50:3959-62.
20. Katayama Y, Zhang HZ, Chambers HF. PBP 2a mutations producing very-high-level resistance to beta-lactams. Antimicrob Agents Chemother. 2004; 48:453-9.
21. Azoulay-Dupuis E, Bedos JP, Mohler J et al. Efficacy of BAL5788, a prodrug of cephalosporin BAL9141, in a mouse model of acute pneumococcal pneumonia. Antimicrob Agents Chemother. 2004; 48:1105-11. (Pubitemid 38405461)
22. Bogdanovich T, Ednie LM, Shapiro S et al. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother. 2005; 49:4210-9. (Pubitemid 41400966)
23. Clark C, Bogdanovich T, Ednie LM et al. Low propensity of ceftobiprole to select for resistant mutuants of H. influenzae and M. catarrhalis. Paper presented at 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, LA; 2005.
24. Queenan AM, Shang W, Kania M et al. Interactions of ceftobiprole with betalactamases from molecular classes A to D. Antimicrob Agents Chemother. 2007; 51:3089-95. (Pubitemid 350067513)
25. Jones ME. In-vitro profile of a new betalactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect. 2007; 13(suppl 2):17-24. (Pubitemid 46711385)
26. Baum EZ, Crespo-Carbone SM, Foleno BD et al. MexXY expression in Pseudomonas aeruginosa (PsA) and susceptibility to cephalosporins, including ceftobiprole. Paper presented at 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Annual Meeting of the Infectious Diseases Society of America. Washington, DC; 2008.
27. Queenan AM, Shang W, Crespo-Carbone SM et al. Mechanisms of ceftobiprole and ceftazidime resistance development in gram-negative clinical isolates from cSSSI subjects. Paper presented at 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Annual Meeting of the Infectious Diseases Society of America. Washington, DC; 2008.
28. Schmitt-Hoffmann A, Roos B, Schleimer M et al. Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob Agents Chemother. 2004; 48:2570-5. (Pubitemid 38823426)
29. Schmitt-Hoffmann A, Nyman L, Roos B et al. Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob Agents Chemother. 2004; 48:2576-80. (Pubitemid 38823427)
30. Roos B, Schmitt-Hoffmann A, Schleimer M et al. Safety and pharmacokinetics of BAL5788 in healthy subjects with normal or impaired renal function. Paper presented at 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; 2003.
31. Murthy B, Skee D, Vaccaro N et al. Open-label pharmacokinetic study of ceftobiprole in healthy subjects and subjects with end-stage renal disease receiving hemodialysis. Paper presented at 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Annual Meeting of the Infectious Diseases Society of America. Washington, DC; 2008.
32. Murthy B, Skee D, Wexter D et al. Pharmacokinetics of ceftobiprole following single and multiple intravenous infusions administered to healthy subjects. Paper presented at 17th European Congress of Clinical Microbiology and Infectious Diseases. Munich, Germany; 2007.
33. Zeftera (ceftobiprole medocaril) package insert. Toronto, Ontario, Canada: Janssen-Ortho; 2008.
34. Andes D, Craig W. In-vivo pharmacodynamics of RO 63-9141 against multiple bacterial pathogens. Paper presented at 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada; 2000.
35. Mouton JW, Schmitt-Hoffmann A, Shapiro S et al. Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141. Antimicrob Agents Chemother. 2004; 48:1713-8.
36. Lodise TP Jr, Pypstra R, Kahn JB et al. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects. Antimicrob Agents Chemother. 2007; 51:2378-87. (Pubitemid 47047314)
37. Leonard SN, Cheung CM, Rybak MJ. Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2008; 52:2974-6.
38. Hilliard JJ, Foleno B, Wira E et al. Effects of ceftobiprole and vancomycin combinations in vitro and in vivo against Staphylococcus aureus. Paper presented at 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Annual Meeting of the Infectious Diseases Society of America. Washington, DC; 2008.
39. Arias CA, Singh KV, Panesso D et al. Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including beta-lactamase-producing and vancomycin-resistant isolates. Antimicrob Agents Chemother. 2007; 51:2043-7. (Pubitemid 46903092)
40. Kresken M, Heep M. In vitro activity of ceftobiprole in combination with ciprofloxacin, levofloxacin, amikacin, and tobramycin against clinical isolates of Pseudomonas aeruginosa. Paper presented at 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, LA; 2005.
41. Pankuch GA, Appelbaum PC. Postantibiotic effect of ceftobiprole against 12 gram-positive organisms. Antimicrob Agents Chemother. 2006; 50:3956-8. (Pubitemid 44684927)
42. Craig WA, Andes DR. In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models. Antimicrob Agents Chemother. 2008; 52:3492-6.
43. Noel GJ, Strauss RS, Amsler K et al. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob Agents Chemother. 2008; 52:37-44.
44. Noel GJ, Bush K, Bagchi P et al. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skinstructure infections. Clin Infect Dis. 2008; 46:647-55. (Pubitemid 351321545)
45. ClinicalTrials.gov. A study of ceftobiprole in patients who have a fever and have abnormally low numbers of the white blood cells called neutrophils in the blood stream (neutropenia). http://clinicaltrials. gov/ct2/show/NCT00529282? term=nct00529282&rank=1 (accessed 2010 Apr 26).
46. ClinicalTrials.gov. Ceftobiprole in the treatment of hospitalized patients with staphylococcus aureus bacteremia. http://clinicaltrials.gov/ct2/ show/NCT0050525 8?term=nct00505258&rank=1 (accessed 2010 Apr 26).
47. Rouse MS, Steckelberg JM, Patel R. In vitro activity of ceftobiprole, daptomycin, linezolid, and vancomycin against methicillin-resistant staphylococci associated with endocarditis and bone and joint infection. Diagn Microbiol Infect Dis. 2007; 58:363-5.
48. Chambers HF. Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother. 2005; 49:884-8.
49. Noel GJ, Strauss RS, Shah A et al. Ceftobiprole versus ceftazidime combined with linezolid for treatment of patients with nosocomial pneumonia. Paper presented at 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Annual Meeting of the Infectious Diseases Society of America. Washington, DC; 2008.
50. Nicholson SC, Strauss RS, Michiels B et al. Efficacy of ceftobiprole compared to ceftriaxone ± linezolid for treatment of subjects hospitalized with community-acquired pneumonia. Paper presented at International Conference of the American Thoracic Society. Toronto, Canada; 2008.
51. Basilea Pharmaceutica Ltd. FDA issues ceftobiprole complete response letter. www.basilea.com/chameleon//outbox//public/29/20091230-Final-PR-Cefto- FDA-3rd-CR-Letter-3-1-E.pdf (accessed 2010 Mar 15).
52. Johnson & Johnson. FDA issues complete response letter for ceftobiprole. www.jnj.com/connect/news/all/20091230-090000 (accessed 2010 Mar 15).